Navigation Links
TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011
Date:3/11/2011

CHENGDU, China, March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals is invited to present at the 23rd ROTH Annual OC Growth Stock Conference from March 13 - 16, 2011 at the Ritz Carlton in Dana Point, California.

Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Board Director of the Company will present at 8:30 am, March 16, at track 2 of the Conference.

An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com

About TPITPI, headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

More information regarding the Company can be found at: http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
http://www.tianyinpharma.comEmail:   Dr.Tong@tianyinpharma.comTel:
+86-28-8551-6696 (Chengdu, China)+86-134-3655-0011 (China)+1-949-350-6999 (U.S.)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Attends North American Bio Forum at Canadian Government Invitation
2. US Oncology Clinical Development Attends Partnerships With CROs
3. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. UBM Announces Content for 10th Annual Japanese Pharma & Bio Events
5. 6th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D.
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
9. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
10. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
11. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
Breaking Biology Technology:
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):